Today, Alliance Foundation Trials, LLC (AFT) was informed that the U.S. Food and Drug Administration has approved palbociclib in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for adult patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–positive (HER2+) locally advanced or metastatic breast cancer following induction treatment. This marks a major milestone and offers new hope for individuals living with this challenging subtype of advanced breast cancer.

 A new Houston Methodist study highlights a promising noninvasive imaging technique that could help doctors more accurately diagnose papillary thyroid cancer, the most common type of thyroid cancer. 

New research among lung cancer screening participants has found that low-dose chest computed tomography (CT) screening is generally well tolerated both physically and emotionally, but experiences vary across socioeconomic groups. Lower-income and safety-net participants experienced higher testing-related burden, with factors such as insurance and employment status associated with more discomfort or anxiety. The findings in the Journal of the American College of Radiology, published by Elsevier, highlight opportunities to improve equity in screening.

Michigan State University researchers have identified how ovarian cancer cells become resistant to chemotherapy and discovered a protein, that, when blocked, can restore the drug’s effectiveness.